linjc16/ctgov huggingface dataset:
Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

Official Title
-----------------
Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Conditions
-----------------
Secondary Bacterial Infection in COVID-19 Patients

Intervention / Treatment
-----------------
* Drug: Colistin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Covid-19 patients with secondary gram-negative bacterial infections Exclusion Criteria: Patients with resistant bacterial strains to polymyxins patients less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Colistin IV<br> | Drug: Colistin<br>* COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized<br>|
| Active Comparator: Colistin Aerosolized<br> | Drug: Colistin<br>* COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbial eradication |  | 10 days | 
| Mortality |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nephrotoxicity |  | 10 days |
Analysis of Suicide Dynamics in Link to the COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
Covid is a virus that first appeared in China in 2019 and was quickly described as a pandemic virus by its globalized nature. The unprecedented occurrence of the virus has led to several health and restrictive government measures. The Covid-19 pandemic and health measures have been able to contribute to the deterioration of the mental health of citizens as it has already been observed during the former pandemic context (Sars covid in 2003 in China or the Spanish flu). Among the consequences of a negative impact on mental health, investigators assume that there is an increase in transitions to the completed suicidal act. However, current studies and observations tend to note that there has been no major change in the dynamics of successful suicides during the Covid period. However, there are biases in the studies conducted: some suicide deaths may have been hidden and not reported as such, due to several factors. For example, the measure of the evolution of suicide attempts that was most often made by the measure of the evolution of the number of hospitalizations for this reason can be a source ofestimate whether people who did this gesture were not hospitalized after a visit to the emergency room or if they gave up attending because of the pandemic. Moreover, suicide deaths are more difficult to report as such when they occur at home than after hospitalization. It is therefore interesting to study the dynamics of suicide during this health crisis retrospectively based on data from the Strasbourg Institute of Forensic Medicine containing the census of the Alsace region, which was hit hard by the pandemic.

Official Title
-----------------
Analysis of Suicide Dynamics in Link to the COVID-19 Pandemic

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient Died between 01/01/2018 and 12/31/2021 Absence of opposition from the patient expressed in writing during his lifetime to the reuse of his personal data for scientific research purposes. Exclusion Criteria: Presence of opposition by the patient expressed in writing during his lifetime to the reuse of his personal data for scientific research purposes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Suicide rates before and after the Covid-19 pandemic |  | from January 1, 2018 to December 31, 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, Suicide
Perioperative Care and Short-term Outcomes of Colorectal Surgery in Addis Abeba

Study Overview
=================
Brief Summary
-----------------
Observational cohort study of adult patients undergoing colorectal surgery at Tikur Anbessa Specialized Hospital in Addis Abeba for 3 months.

Detailed Description
-----------------
Observational prospective cohort study, including all adult (≥18) patients undergoing colorectal surgery at Tikur Anbessa Specialized Hospital in Addis Abeba for 3 months. Variables are patients' characteristics, risk factors, investigations, types of operations, level of training of surgeon, and postoperative management. The data collection is conducted at admission, day of surgery, and discharge. The primary outcomes are in-hospital complications and length of stay, and the secondary outcomes are perioperative management.

Official Title
-----------------
Perioperative Care and Short-term Outcomes of Colorectal Surgery: A Prospective Study From Tikur Anbessa Specialized Hospital in Addis Abeba Ethiopia

Conditions
-----------------
Colorectal Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Willingness and ability to give informed consent Admitted to the surgical department at TASH (elective or in an emergency) and operated for a colorectal condition Exclusion Criteria: -Emergency conditions usually managed in general surgery, e.g., perianal conditions and adhesive small bowel obstruction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion postoperative complications | Number and proportion (%) of patients with any postoperative complication according to Clavien-Dindo | From date of surgery to date of discharge from hospital or maximun 30 days postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean length of stay | Mean number of days in hospital | From admission to date of discharge from hospital, up to 30 days | 
| Type of surgery performed | Number and proportion (%) of colorectal operations performed (colectomy, rectal resection, stoma without resection) | From admission to date of discharge from hospital, up to 30 days |
Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary research at Toulouse University Hospital suggests urinary S1P levels may be a potential biomarker for detrusor activity in MS. This study aims to confirm this potential biomarker's utility.

Official Title
-----------------
Prospective Study Evaluating the Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Other: S1P level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: French residents enrolled in the social security system Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not Patients scheduled for urodynamic assessment as part of their management Exclusion criteria: Pregnant or lactating females Patients under legal guardianship Untreated urinary tract infection at the time of inclusion Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| multiple sclerosis<br>Patients diagnosed with MS requiring urodynamic assessment will be recruited during outpatient visits at Toulouse University Hospital. Initial consultations will involve questionnaire completion, 72-hour voiding diaries, and urine sample collection just before urodynamic assessments. | Other: S1P level<br>* Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| S1P concentration | To compare of the urinary concentration of S1P related to creatinine in urine sample, as a function of the detrusor activity determined at BUD, before and after a first intra-detrusor injection of botulinum toxin. | Day 0, after 6 months |
Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation

Study Overview
=================
Brief Summary
-----------------
Follitropin delta (Rekovelle) algorithm established by Ferring provides personalized gonadotrophin doses based on each patient's weight and AMH. As a result, risks of stimulation failure or ovarian hyperstimulation syndrome (OHSS) during an in vitro fertilization (IVF) cycle are minimized. As a standard practice for OHSS prevention at clinique ovo, women undergoing IVF will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. However, with the determination of the Rekovelle and Menopur algorithm, the risks of OHSS before the tenth day have been considerably minimized.

Detailed Description
-----------------
The purpose of this study is to evaluate the necessity of programming an ultrasound and blood test prior to the tenth day of ovarian stimulation when women are on personalized doses of Rekovelle and Menopur duting an antagonist IVF cycle. Based on the results of the analysis, we will assess the economic impact that programming an ultrasound and blood test at day 10 might have.

Official Title
-----------------
Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation

Conditions
-----------------
Infertility, IVF

Intervention / Treatment
-----------------
* Other: Study chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women of 18 years of age or older having provided consent to chart access for scientific publication in the IVF consent form Antagonist IVF cycle using combination of Rekovelle and Menopur for stimulation according to the modified protocol employed at clinique ovo without deviation Presence of both ovaries Exclusion Criteria: Second cycle of Duo-Stim IVF

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women undergoing IVF<br>Women undergoing an antagonist in vitro fertilization cycle using Rekovelle and Menopur for stimulation | Other: Study chart review<br>* Evaluation of the IVF cycle using the prescribed medication<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify the population where a simplified IVF monitoring is conceivable | Rate of Rekovelle and / or Menopur dose modification before day 10 ultrasound | Up to 3 weeks |
Changes in Gene Expression and Prognosis of Blood Immune Cells After Cardiopulmonary Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the changes in gene expression in blood immune cells in after cardiac surgery with cardiopulmonary bypass.The main question it aims to answer is: What specific gene expression changes predict kidney damage after cardiac surgery with cardiopulmonary bypass. Participants received conventional treatment.

Official Title
-----------------
Changes in Gene Expression and Prognosis of Blood Immune Cells After Cardiopulmonary Bypass Surgery

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: Gene sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Age≥ 18 years old; 2) Cardiopulmonary bypass descending valve replacement (molding), or coronary artery bypass grafting, or macrovascular surgery. Exclusion Criteria: 1) any cognitive or mental impairment that is unable to sign the informed consent form; 2) Have basic immune system and blood system diseases; 3) pregnancy; 4) Receiving radiotherapy and chemotherapy before surgery; 5) Receiving immunosuppressive drugs within six months; 6) Have participated in other interventional clinical trials within 30 days before surgery. Exit Criteria: Incomplete surgery; Secondary transfer in the operating room; Automatically request to terminate the test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Postoperative acute kidney injury<br> | Other: Gene sequencing<br>* Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery<br>|
| Postoperative non-acute kidney injury<br> | Other: Gene sequencing<br>* Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative acute kidney injury | SCr was elevated ≥ 26.5 micromol/L or 1.5 times the baseline for SCr ≥ or urine output < 0.5 mL/kg/hour within 6 hours within 48 hours | Within 48 hours after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute kidney injury, Cardiopulmonary bypass, gene expression
A Cohort Establishment Study of Total Management of Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Detailed Description
-----------------
To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer); To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures; The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed; To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Official Title
-----------------
A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)

Conditions
-----------------
Tumor of Female Reproductive System, Ovarian Cancer

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital; Can cooperate with later follow-up. Exclusion Criteria: Patients with other malignant tumors or previous history of other malignant tumors; Have cognitive impairment.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progress Freesurvival (PFS) | The time from the start of treatment until the patient progresses further or dies. | Average six months after study completion. | 
| Overall Survival (OS) | Measure the time from the start of treatment to the time of death. | Average six months after study completion. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of adverse reactions | All adverse events were recorded. | Average six months after study completion. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian cancer, Cohort study, Whole-process management
Harassment of Pain Clinic Staff by Patients

Study Overview
=================
Brief Summary
-----------------
Chronic pain is associated with psychological disorders, and many patients have behavioral problems. Some patients harass pain services staff. Most healthcare staff do not report harassment by patients. Quantitative and qualitative analysis of prospective electronic and clinic diary data. Evaluation of incidents of clinic staff harassment; caused by patients and patients' family. Analysis of causative factors, incident outcome and lessons learned.

Detailed Description
-----------------
Chronic pain is associated with psychological and mental health disorders. Many patients have personality and behavioral disorders. Some patients harass their pain care providers. Most healthcare staff do not report harassment by patients. This is a quantitative and qualitative analysis of prospective electronic and clinic diary data. It is an evaluation of incidents of pain clinic staff harassment; caused by patients and patients' family. This is an analysis of incident causative factors, incident outcome and lessons learned. The qualitative information of each incident is presented in a sensitive and careful format.

Official Title
-----------------
Harassment of Pain Clinic Staff by Chronic Pain Patients

Conditions
-----------------
Patient Violence

Intervention / Treatment
-----------------
* Behavioral: Behavioral therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult chronic pain patients Exclusion Criteria: pediatric chronic pain patients

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult chronic pain patients<br>Adult chronic pain patients who harass pain clinic staff | Behavioral: Behavioral therapy<br>* Behavioral and supportive therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who harassed clinic staff | Percentage of patients who harassed clinic staff | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Harassment by patients